Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals — FY2023 Earnings Presentation

39 slides from Day One Biopharmaceuticals's earnings presentation, Feb 26, 2024

  1. Slide 1: Targeted Therapies for People of All Ages

    Day One Biopharmaceuticals Targeted Therapies for People of All Ages February 2024

  2. Slide 2: Disclaimer

    Disclaimer This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements are inherently subject to risks and uncertainties, some

  3. Slide 3: Cancer Therapies for People of All Ages

    Cancer Therapies for People of All Ages Develop medicines for genomically-defined cancers Establish first-in-class position through rapid registration pathways Expand to adolescent and adult populations in parallel and pursue those opportunities with the same commitment we do for children Our Approa

  4. Slide 4: Our Pipeline

    * FIREFLY-1 Arm 1 expected to support registration. † Pimasertib Phase 1 dose escalation and expansion trial previously completed. † † Includes patients ≥12 years of age. § Research collaboration and license agreement with Sprint Bioscience AB for exclusive worldwide rights to a research-stage progr

  5. Slide 5: Tovorafenib (DAY101) Type II RAF Inhibitor

    Tovorafenib (DAY101) Type II RAF Inhibitor

  6. Slide 6: Kids like Sawyer spend most of their childhood as patients

    Sawyer, lives with pLGG. 1 Figures come from FIREFLY-1 baseline patient characteristics with a June 5, 2023 data cutoff. Total patients enrolled in arm 1 of the FIREFLY-1 trial was 77. Kids like Sawyer spend most of their childhood as patients rather than children 3 (1-9) 51% Median (range) number o

  7. Slide 7: Pediatric Low-Grade Glioma: Most Common Brain Tumor In Children

    Pediatric Low-Grade Glioma (pLGG): The Most Common Type Of Brain Tumor In Children A Serious and Life-Threatening Disease pLGGs are chronic and relentless, with patients suffering profound tumor and treatment-associated morbidity that can impact their life trajectory over the long term9 1 CBTRUS, Qa

  8. Slide 8: Sources

    Source: 1. Heitzer AM, Raghubar K, Ris MD, et al. Neuropsychological functioning following surgery for pediatric low-grade glioma: a prospective longitudinal study. J Neurosurg Pediatr. 2019;1-9. doi:10.3171/2019.9.PEDS19357. 2. Bryant R. Managing side effects of childhood cancer treatment. J Pediat

  9. Slide 9: Tovorafenib Inhibits Both BRAF Fusions And BRAF V600 Mutations

    Tovorafenib (DAY101) Inhibits Both BRAF Fusions And BRAF V600 Mutations Tovorafenib (DAY101) is an investigational, oral, selective, CNS-penetrant, type II RAF inhibitor that was designed to inhibit both monomeric and dimeric RAF kinase Activity in tumors driven by both RAF fusions and BRAF V600E mu

  10. Slide 10: Pivotal Phase 2 Trial Of Tovorafenib In Relapsed Or Progressive pLGG (FIREFLY-1)

    June 5, 2023 data cutoff. 1 Wen PY, et al. J Clin Oncol. 2010;28(11):1963-1972. 2 Fangusaro J, et al. Lancet Oncol. 2020;21(6):e305–316. 3 van den Bent MJ, et al. Lancet Oncol. 2011;12(6):583-593. Abbreviations: CBR, clinical benefit rate; IRC, independent review committee; C, cycle; D, day; LGG, lo

  11. Slide 11: Data from Pivotal Phase FIREFLY-1 Trial

    Data from Pivotal Phase 2 FIREFLY-1 Trial June 5, 2023 data cutoff

  12. Slide 12: FIREFLY-1 Baseline Patient Characteristics

    FIREFLY-1 Baseline Patient Characteristics June 5, 2023 data cutoff. *Includes 6 patients with BRAF duplication and 2 with BRAF rearrangement per fluorescence in situ hybridization or in situ hybridization. †Includes tumors that were extending into multiple regions of the brain, leptomeningeal disea

  13. Slide 13: Tumor Response To Tovorafenib Using RAPNO-LGG, RANO-LGG and RANO-HGG

    Tumor Response To Tovorafenib (DAY101) Using RAPNO-LGG, RANO-LGG and RANO-HGG Maximum change in tumor size (%) Maximum change in tumor size (%) Maximum change in tumor size (%) RAPNO-LGG RANO-LGG RANO-HGG June 5, 2023 data cutoff. BOR, best overall response; CBR, clinical benefit rate; CI, confidenc

  14. Slide 14: Duration Of Tovorafenib Therapy With RAPNO-LGG Evaluable Lesions

    Duration Of Tovorafenib (DAY101) Therapy For All Patients With RAPNO-LGG Evaluable Lesions June 5, 2023 data cutoff. Patients Overall treatment duration (months) 5.3 Months 13.8 Months Median time to response Median duration of treatment

  15. Slide 15: Tumor Kinetics In Patients With Best Response Of Progressive Disease

    Tumor Kinetics In Patients With Best Response Of Progressive Disease According To RAPNO-LGG June 5, 2023 data cutoff. Change in tumor size (%) Months The majority of patients who had radiographic progression by RAPNO-LGG at their initial disease assessment had subsequent prolonged reductions in the

  16. Slide 16: Tumor Response According To RAPNO-LGG In Subgroups

    Tumor Response To Tovorafenib (DAY101) According To RAPNO-LGG In Subgroups Defined By Baseline Characteristics June 5, 2023 data cutoff. Other races included Asian (n=5), Black (n=2), Multiple (n=3),and Other (n=6). There were no Native Hawaiian or other Pacific Islander or American Indian or Alaska

  17. Slide 17: Tumor Response Consistent Across BRAF Fusion And Mutation Patients

    Tumor Response To Tovorafenib (DAY101) Across Three Assessment Criteria Were Consistent Across BRAF Fusion And Mutation Patients, and Patients With Prior MAPK Treatment June 5, 2023 data cutoff. 1 Fangusaro J, et al. Lancet Oncol. 2020;21(6):e305–316. 2 Fangusaro J, et al. Lancet Oncol. 2020;21(6):e

  18. Slide 18: Tovorafenib Safety Data (n=137)

    Tovorafenib (DAY101) Safety Data (n=137) June 5, 2023 data cutoff. Treatment-emergent AEs ≥25% any grade in arms 1 & 2. AE, adverse event; ALT, Alanine transaminase; AST, aspartate aminotransferase; COVID-19, Coronavirus disease 2019; CPK, creatine phosphokinase; LDH, lactate dehydrogenase; RTI, res

  19. Slide 19: References

    1 Selt F, van Tilburg CM, Bison B, et al. Response to trametinib treatment in progressive pediatric low-grade glioma patients. J Neurooncol. 2020;149(3):499-510. doi:10.1007/s11060-020-03640-3. 2 Ryall S, Tabori U, Hawkins C. Pediatric low-grade glioma in the era of molecular diagnostics. Acta Neuro

  20. Slide 20: Preparing for a Successful Launch

    Preparing for a Successful Launch* * Pending FDA Approval Key Factors Communicate strong clinical profile for tovorafenib without significant disruption to childhood Enable patient access through establishing broad coverage and patient support programs Experienced, fully dedicated field sales force

  21. Slide 21: Key Takeaways From FIREFLY-1 Data And Next Steps

    Key Takeaways From FIREFLY-1 Data And Next Steps Response rate is clinically meaningful from FIREFLY-1 for pediatric patients with recurrent or progressive LGG harboring BRAF fusions or BRAF V600E mutations (“BRAF-altered”) 67% ORR by RANO-HGG 51% ORR by RAPNO-LGG 53% ORR by RANO-LGG Deepening of re

  22. Slide 22: FIREFLY-2 / LOGGIC Pivotal Phase Trial in Frontline pLGG

    FIREFLY-2 / LOGGIC Pivotal Phase 3 Trial of Tovorafenib (DAY101) in Frontline pLGG

  23. Slide 23: FIREFLY-2/LOGGIC Pivotal Phase Trial In Frontline pLGG

    FIREFLY-2/LOGGIC Pivotal Phase 3 Trial Of Tovorafenib (DAY101) In Frontline pLGG Trial Design * COG or SIOPe-LGG regimen. Abbreviations: CHG, chiasmatic, hypothalamic glioma; DoR, duration of response; LGG, low-grade glioma; ORR, objective response rate; QoL, quality of life; QW, once weekly; SoC, s

  24. Slide 24: FIRELIGHT-1 Phase 1b/2 Trials of Tovorafenib with Pimasertib

    FIRELIGHT-1 Phase 1b/2 Trials Evaluating Tovorafenib (DAY101) as a Combination with Pimasertib

  25. Slide 25: Pimasertib: Investigational Allosteric MEK1/2 Inhibitor

    Pimasertib: Investigational Allosteric MEK1/2 Inhibitor With Demonstrated Activity In MAPK-Driven Solid Tumors Pimasertib is an investigational orally-bioavailable, selective, non-competitive MEK1/2 inhibitor in-licensed from Merck KGaA in February 2021 Extensive non-clinical and clinical developmen

  26. Slide 26: Vertical MAPK Pathway Inhibition With Tovorafenib And Pimasertib

    Vertical MAPK Pathway Inhibition With Tovorafenib (DAY101) And Pimasertib May Unlock Potential Synergy For Adult Solid Tumors KRAS or NRAS mutant BRAF non-V600 mutant MEK ERK RAF/ MEK/ERK PI3K/m TOR PI3K/m TOR Proliferation, survival Proliferation, survival Type II RAFi + MEKI Type II RAFi + MEKI No

  27. Slide 27: Tovorafenib / Pimasertib Combination In Solid Tumors (FIRELIGHT-1) Trial Design

    NRASmut Selected tumors Pre-identified patients with advanced solid tumors and available clinical molecular profiling information. Tovorafenib (DAY101) / Pimasertib Combination In Solid Tumors (FIRELIGHT-1) Trial Design1 Abbreviations: BOIN, Bayesian Optimal Interval Design; BRAF, B-Raf proto-oncoge

  28. Slide 28: Summary

    Summary

  29. Slide 29: Financial Summary: DAWN

    Financial Summary: DAWN All financial and share information is unaudited. 1NDA data set includes analysis of primary (ORR by RANO-HGG) and secondary (ORR by RAPNO, PFS) efficacy endpoints, safety, and exploratory analyses (including ORR by RANO-LGG). PRV, Priority Review Voucher. $ Millions Twelve M

  30. Slide 30: 2023 Key Accomplishments

    2023 Key Accomplishments FIREFLY-1: Relapsed or Progressive pLGG Business Development Financials $366.3 million in cash, cash equivalents and short-term investments as of December 31, 2023 Cash runway into 2026 Research collaboration and license agreement for preclinical program targeting VRK1 in Au

  31. Slide 31: Priorities as we Expand into a Commercial-Stage Company

    Priorities as we Expand into a Commercial-Stage Company Secure the first FDA-approved targeted therapy for pLGG with BRAF fusions and point mutations that have relapsed or progressed Expand awareness amongst physicians and establish broad coverage to enable patient access Following approval, establi

  32. Slide 32: Appendix

    Day One x Appendi 32

  33. Slide 33: Duration Of Tovorafenib Therapy With RANO-HGG Evaluable Lesions

    Duration Of Tovorafenib (DAY101) Therapy For All Patients With RANO-HGG Evaluable Lesions Patients Overall treatment duration (months) June 5, 2023 data cutoff. 3.0 Months 16.6 Months Median time to response Median duration of treatment

  34. Slide 34: Duration Of Tovorafenib Therapy With RANO-LGG Evaluable Lesions

    Duration Of Tovorafenib (DAY101) Therapy For All Patients With RANO-LGG Evaluable Lesions Patients Overall treatment duration (months) June 5, 2023 data cutoff. 5.5 Months 14.4 Months Median time to response Median duration of treatment

  35. Slide 35: Case Study: Tovorafenib In KIAA1549-BRAF Fusion Optic Pathway Glioma

    Case Study: Activity Of Tovorafenib (DAY101) In KIAA1549-BRAF Fusion Optic Pathway Glioma A 7-years-old female child with an optic pathway glioma, with very poor vision, entropion, folliculitis, eczema, mouth ulceration and xerosis Apr 14, 2022 data cutoff. Tovorafenib is an investigational agent. S

  36. Slide 36: Case Study: Tovorafenib In KIAA1549-BRAF Fusion Posterior Fossa Pilocytic Astrocytoma

    PR (-69%) at cycle 3 with 500 mg QW tovorafenib, with a deepening of response (80% and 91% in cycles 6 and 9, respectively) over time AEs included grade 2 decrease in neutrophil count, pustular rash, and upper respiratory infection Patient continues to receive weekly tovorafenib Tovorafenib Case Stu

  37. Slide 37: Case Study: Tovorafenib In BRAF V600E Mutation Deep Midline Astrocytoma

    PR (-74%) at cycle 3, with a deepening of response (-94%) at cycle 6 AEs included grade 3 maculopapular rash and increased CPK, requiring drug interruption and dose reduction (500 mg QW to 400 mg QW in cycle 1) Tovorafenib dose was re-escalated back to 500 mg QW in cycle 4; patient continues on trea

  38. Slide 38: Case Study: Tovorafenib In KIAA1549-BRAF Fusion Posterior Fossa Pilocytic Astrocytoma

    Initiated treatment with tovorafenib 400 mg/QW following 3 prior therapies, including binimetinib and trametinib, which were discontinued due to PD At cycle 3, PR (-88%) per RANO-HGG, and MR (-32% and -40%) per RAPNO-LGG and RANO-LGG, respectively Sustained improvements in visual acuity reported; lo

  39. Slide 39: FIREFLY-2/LOGGIC: Pivotal Phase Study In Newly Diagnosed pLGG

    FIREFLY-2/LOGGIC: Pivotal Phase 3 Study Of Tovorafenib (DAY101) In Newly Diagnosed pLGG Collaboration between Day One and the LOGGIC consortium, internationally recognized experts in pLGG research Coupled with the LOGGIC-CORE molecular diagnostic program Worked jointly on the study design and discus

Day One Biopharmaceuticals — FY2023 Earnings Presentation on 6ix